Patıents乳腺癌患者体内白三烯D4水平

Q3 Pharmacology, Toxicology and Pharmaceutics

Fabad Journal of Pharmaceutical Sciences Pub Date : 2022-06-16 DOI:10.55262/fabadeczacilik.1086291

S. Akaydin, Sümeyye Ramazanoğlu, Ece MİSER SALİHOĞLU, H. Karanlık, S. Demokan

{"title":"Patıents乳腺癌患者体内白三烯D4水平","authors":"S. Akaydin, Sümeyye Ramazanoğlu, Ece MİSER SALİHOĞLU, H. Karanlık, S. Demokan","doi":"10.55262/fabadeczacilik.1086291","DOIUrl":null,"url":null,"abstract":"Leukotriene D4 (LTD4) is an inflammatory mediator synthesized in the arachidonic acid pathway and has been reported to induce cell proliferation and survival in cancer. LTD4 is synthesized from LTC4 by the enzyme gamma-glutamyltransferase (GGT). Here, we examined serum LTD4 levels and the relationship of LTD4 with GGT in patients with breast cancer. For that purpose, serum samples were taken from 43 patients diagnosed with breast cancer and 8 healthy controls. The patients were divided into five subgroups, as Luminal A, Luminal B, Luminal B-HER2(+), HER2(+) and triple negative. LTD4 levels were measured by ELISA method. Mean levels of LTD4 in the patients were significantly higher than in healthy controls [3,43 (2,21) ng/mL vs 1,47 (0,46) ng/mL; p < 0.05]. According to the molecular subtypes, serum LTD4 levels were found to be significantly higher in the Luminal A, Luminal B and Triple (-) subgroups than in the controls (p","PeriodicalId":36004,"journal":{"name":"Fabad Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Leukotriene D4 Levels in Patıents With Breast Cancer\",\"authors\":\"S. Akaydin, Sümeyye Ramazanoğlu, Ece MİSER SALİHOĞLU, H. Karanlık, S. Demokan\",\"doi\":\"10.55262/fabadeczacilik.1086291\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Leukotriene D4 (LTD4) is an inflammatory mediator synthesized in the arachidonic acid pathway and has been reported to induce cell proliferation and survival in cancer. LTD4 is synthesized from LTC4 by the enzyme gamma-glutamyltransferase (GGT). Here, we examined serum LTD4 levels and the relationship of LTD4 with GGT in patients with breast cancer. For that purpose, serum samples were taken from 43 patients diagnosed with breast cancer and 8 healthy controls. The patients were divided into five subgroups, as Luminal A, Luminal B, Luminal B-HER2(+), HER2(+) and triple negative. LTD4 levels were measured by ELISA method. Mean levels of LTD4 in the patients were significantly higher than in healthy controls [3,43 (2,21) ng/mL vs 1,47 (0,46) ng/mL; p < 0.05]. According to the molecular subtypes, serum LTD4 levels were found to be significantly higher in the Luminal A, Luminal B and Triple (-) subgroups than in the controls (p\",\"PeriodicalId\":36004,\"journal\":{\"name\":\"Fabad Journal of Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fabad Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55262/fabadeczacilik.1086291\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fabad Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55262/fabadeczacilik.1086291","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

白三烯D4 (LTD4)是花生四烯酸途径合成的一种炎症介质，据报道可诱导肿瘤细胞增殖和存活。LTD4是由LTC4通过谷氨酰转移酶(GGT)合成的。在这里，我们检测了乳腺癌患者血清LTD4水平以及LTD4与GGT的关系。为此，研究人员采集了43名乳腺癌患者和8名健康对照者的血清样本。将患者分为Luminal A、Luminal B、Luminal B-HER2(+)、HER2(+)和三阴性5个亚组。ELISA法检测LTD4水平。患者LTD4的平均水平显著高于健康对照组[3,43 (2,21)ng/mL vs 1,47 (0,46) ng/mL;P < 0.05]。根据分子亚型，Luminal A、Luminal B和Triple(-)亚组的血清LTD4水平明显高于对照组(p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Leukotriene D4 Levels in Patıents With Breast Cancer

Leukotriene D4 (LTD4) is an inflammatory mediator synthesized in the arachidonic acid pathway and has been reported to induce cell proliferation and survival in cancer. LTD4 is synthesized from LTC4 by the enzyme gamma-glutamyltransferase (GGT). Here, we examined serum LTD4 levels and the relationship of LTD4 with GGT in patients with breast cancer. For that purpose, serum samples were taken from 43 patients diagnosed with breast cancer and 8 healthy controls. The patients were divided into five subgroups, as Luminal A, Luminal B, Luminal B-HER2(+), HER2(+) and triple negative. LTD4 levels were measured by ELISA method. Mean levels of LTD4 in the patients were significantly higher than in healthy controls [3,43 (2,21) ng/mL vs 1,47 (0,46) ng/mL; p < 0.05]. According to the molecular subtypes, serum LTD4 levels were found to be significantly higher in the Luminal A, Luminal B and Triple (-) subgroups than in the controls (p

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Fabad Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： The FABAD Journal of Pharmaceutical Sciences is published triannually by the Society of Pharmaceutical Sciences of Ankara (FABAD). All expressions of opinion and statements of supposed facts appearing in articles and/or advertisiments carried in this journal are published on the responsibility of the author and/or advertiser, anda re not to be regarded those of the Society of Pharmaceutical Sciences of Ankara. The manuscript submitted to the Journal has the requirement of not being published previously and has not been submitted elsewhere. Manuscripts should be prepared in accordance with the requirements specified as given in detail in the section of “Information for Authors”. The submission of the manuscript to the Journal is not a condition for acceptance; articles are accepted or rejected on merit alone. All rights reserved.